TY - JOUR
T1 - CRUSE®-An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria
AU - Neisinger, Sophia
AU - Pinto, Bernardo Sousa
AU - Ramanauskaite, Aiste
AU - Bousquet, Jean
AU - Weller, Karsten
AU - Metz, Martin
AU - Magerl, Markus
AU - Kocatuerk, Emek
AU - Cherrez-Ojeda, Ivan
AU - Gimenez-Arnau, Ana M.
AU - Parisi, Claudio Alberto S.
AU - Altrichter, Sabine
AU - Ensina, Luis Felipe
AU - Bouillet, Laurence
AU - Asero, Riccardo
AU - Goncalo, Margarida
AU - Guillet, Carole
AU - Rutkowski, Krzysztof
AU - Bernstein, Jonathan A
AU - Hardin, Hannah
AU - Godse, Kiran
AU - Brzoza, Zenon
AU - Sousa, Jose Ignacio Larco
AU - Thomsen, Simon Francis
AU - van Doorn, Martijn
AU - Hide, Michihiro
AU - Ye, Young‐Min
AU - Vanderse, Staffan
AU - Lapina, L.
AU - Peter, Jonny
AU - Zhao, Zuotao
AU - Han, Lianyi
AU - Nasr, Iman
AU - Rockmann-Helmbach, Heike
AU - Sorensen, Jennifer Astrup
AU - Kara, Rabia Öztaş
AU - Kurjane, N.
AU - Kurchenko, Andrii I.
AU - Kaidashev, Igor
AU - Tsaryk, Vladyslav
AU - Stepanenko, Roman
AU - Maurer, Marcus
N1 - Publisher Copyright:
© 2024 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
PY - 2024/1
Y1 - 2024/1
N2 - Background: Chronic spontaneous urticaria (CSU) is unpredictable and can severely impair patients' quality of life. Patients with CSU need a convenient, user-friendly platform to complete patient-reported outcome measures (PROMs) on their mobile devices. CRUSE®, the Chronic Urticaria Self Evaluation app, aims to address this unmet need. Methods: CRUSE® was developed by an international steering committee of urticaria specialists. Priorities for the app based on recent findings in CSU were defined to allow patients to track and record their symptoms and medication use over time and send photographs. The CRUSE® app collects patient data such as age, sex, disease onset, triggers, medication, and CSU characteristics that can be sent securely to physicians, providing real-time insights. Additionally, CRUSE® contains PROMs to assess disease activity and control, which are individualised to patient profiles and clinical manifestations. Results: CRUSE® was launched in Germany in March 2022 and is now available for free in 17 countries. It is adapted to the local language and displays a country-specific list of available urticaria medications. English and Ukrainian versions are available worldwide. From July 2022 to June 2023, 25,710 observations were documented by 2540 users; 72.7% were females, with a mean age of 39.6 years. At baseline, 93.7% and 51.3% of users had wheals and angioedema, respectively. Second-generation antihistamines were used in 74.0% of days. Conclusions: The initial data from CRUSE® show the wide use and utility of effectively tracking patients' disease activity and control, paving the way for personalised CSU management.
AB - Background: Chronic spontaneous urticaria (CSU) is unpredictable and can severely impair patients' quality of life. Patients with CSU need a convenient, user-friendly platform to complete patient-reported outcome measures (PROMs) on their mobile devices. CRUSE®, the Chronic Urticaria Self Evaluation app, aims to address this unmet need. Methods: CRUSE® was developed by an international steering committee of urticaria specialists. Priorities for the app based on recent findings in CSU were defined to allow patients to track and record their symptoms and medication use over time and send photographs. The CRUSE® app collects patient data such as age, sex, disease onset, triggers, medication, and CSU characteristics that can be sent securely to physicians, providing real-time insights. Additionally, CRUSE® contains PROMs to assess disease activity and control, which are individualised to patient profiles and clinical manifestations. Results: CRUSE® was launched in Germany in March 2022 and is now available for free in 17 countries. It is adapted to the local language and displays a country-specific list of available urticaria medications. English and Ukrainian versions are available worldwide. From July 2022 to June 2023, 25,710 observations were documented by 2540 users; 72.7% were females, with a mean age of 39.6 years. At baseline, 93.7% and 51.3% of users had wheals and angioedema, respectively. Second-generation antihistamines were used in 74.0% of days. Conclusions: The initial data from CRUSE® show the wide use and utility of effectively tracking patients' disease activity and control, paving the way for personalised CSU management.
KW - Chronic urticaria self evaluation (CRUSE (R)) app
KW - Digital tools
KW - MHealth apps
KW - Patient-reported outcome measures
KW - Wheals and angioedema
UR - http://www.scopus.com/inward/record.url?scp=85181927659&partnerID=8YFLogxK
U2 - 10.1002/clt2.12328
DO - 10.1002/clt2.12328
M3 - Article
SN - 2045-7022
VL - 14
JO - Clinical and Translational Allergy
JF - Clinical and Translational Allergy
IS - 1
M1 - e12328
ER -